This is a working overview of lyophilized powder, written for readers who want more than a one-paragraph summary but less than a textbook.
Reviewed 2025-10-11. Anything still debated is marked as such rather than presented as settled.
Two related forms circulate in technical discussion under the same family name. The original version carries a drug affinity complex (DAC) that binds covalently to serum albumin after administration, and this linkage substantially extends circulation time. A second form, frequently written as modified GRF(1-29) or CJC-1295 without DAC, lacks that linker and clears much faster. The naming is a frequent source of confusion because the shorthand CJC-1295 can refer to either form depending on the source. Reports sometimes fail to specify which variant was studied.
The peptide backbone includes a D-alanine at position two, which resists cleavage by dipeptidyl peptidase IV, and several other substitutions that reduce degradation. Its molecular weight is roughly 3.4 kDa without the linker and about 3.6 kDa with it. The molecule is water soluble and is normally supplied as a lyophilized powder. Precise sequence and mass values depend on which variant is described, so technical documents usually state the exact form being referenced.
CJC-1295 is a synthetic peptide designed as a long-acting analogue of growth hormone-releasing hormone (GHRH). Its structure derives from the first 29 amino acids of native GHRH, a fragment often called GRF(1-29). Four substitutions were introduced to slow enzymatic breakdown and extend activity relative to the natural sequence. The compound was developed by ConjuChem as part of a broader effort to improve the pharmacokinetic profile of peptide hormones. It is studied in laboratory and clinical research settings rather than appearing as a naturally occurring substance.
CJC-1295 belongs to a class of synthetic peptides modeled on growth hormone releasing hormone, a forty-four amino acid signal produced by the hypothalamus. The compound is built from the first twenty-nine residues of the natural sequence, with four substitutions introduced at positions 2, 8, 15 and 27. These changes were designed to slow enzymatic breakdown while preserving receptor activation. The result is a peptide that is shorter than native GHRH and considerably more resistant to ordinary clearance pathways in circulation.
Two related forms appear under the CJC-1295 name. The simpler analogue, commonly written as modified GRF(1-29), carries the four substitutions but no additional conjugation. The second form attaches a maleimidopropionic acid linker to a lysine residue, a modification frequently called the drug affinity complex. That linker reacts with the free thiol on serum albumin to form a covalent bond. Because albumin has a long residence time in blood, the conjugated peptide stays in circulation far longer than the unconjugated analogue.
| Property | Value | Notes |
|---|---|---|
| Molecular weight (no linker) | ~3.37 kDa | Calculated from peptide sequence |
| Molecular weight (with linker) | ~3.65 kDa | Includes albumin-binding moiety |
| Appearance | White to off-white powder | Typically lyophilized |
| Solubility | Soluble in water | Also dissolves in aqueous buffers |
| Common synonyms | Modified GRF(1-29), DAC:GRF | Usage varies by source |
CJC-1295 is a synthetic analogue of growth hormone-releasing hormone, built on the 29-amino-acid GHRH(1-29) fragment. Four substitutions distinguish it from the natural sequence: D-alanine at position 2, glutamine at position 8, alanine at position 15, and leucine at position 27. These changes reduce enzymatic cleavage and extend the peptide's persistence in circulation. The compound is discussed in two forms, one carrying a drug affinity complex and one without it.
The drug affinity complex is a maleimidopropionic acid group attached to a lysine side chain. It reacts with the free thiol of cysteine-34 on circulating albumin, forming a covalent bond. This conjugation keeps the peptide in the bloodstream and shields it from rapid renal filtration and proteolysis. Reported circulation half-lives for the albumin-bound form fall in the range of roughly six to nine days in early human studies.
Binding to GHRH receptors on pituitary somatotroph cells triggers cyclic AMP signaling and stimulates growth hormone synthesis and release. Because the peptide acts upstream of the pituitary, effects are mediated through endogenous growth hormone rather than direct receptor activation in peripheral tissues. Increases in insulin-like growth factor 1 are generally described as a downstream consequence. Most published human exposure data come from small early-stage studies, and the clinical significance of the pharmacokinetic profile remains incompletely characterized.
Binding of the peptide to the growth hormone-releasing hormone receptor on pituitary somatotrophs triggers a G protein coupled cascade that raises cyclic AMP and opens calcium channels. The result is greater secretion of growth hormone into the bloodstream. Because the peptide acts at the same receptor as the natural hypothalamic hormone, its effect is amplified pulse size rather than an entirely separate release pathway. Receptor binding alone does not determine the response, since somatostatin tone and other inputs modulate the final output.
The albumin-binding version stays in circulation for days, because covalent attachment to serum albumin shields the peptide from rapid filtration and degradation. Reported half-lives for this form fall in the range of several days. The version without the linker is cleared in minutes, with estimates often near thirty minutes in animal work. These figures come from small studies and vary with assay method, species, and route, so they are best read as approximate rather than fixed constants.
CJC-1295 acts at the growth hormone-releasing hormone receptor, a G-protein-coupled receptor found on somatotroph cells in the anterior pituitary. Binding triggers a rise in cyclic AMP and calcium entry, which promotes release of stored growth hormone. Because the peptide mimics the body's own releasing hormone, it amplifies existing secretory pulses rather than driving continuous output. The size of the response therefore depends partly on the subject's own hormonal rhythm and feedback state.
The attached maleimide group explains the unusual duration of the DAC version. After injection it reacts with the thiol of cysteine-34 on serum albumin, forming a stable covalent bond. The resulting conjugate is too large for rapid kidney filtration and is shielded from many peptidases. Reported half-lives for this form reach several days, whereas the version without the group is cleared in roughly half an hour. That gap is the main pharmacological difference between the two.
=== Non-diabetics === In those with hypoglycemia who do not have diabetes, there are a number of preventative measures dependent on the cause. Hypoglycemia caused by hormonal dysfunction like lack of cortisol in Addison's disease or lack of growth hormone in hypopituitarism can be prevented with appropriate hormone replacement. The hypoglycemic episodes associated with non-B cell tumors can be decreased following surgical removal of the tumor, as well as following radiotherapy or chemotherapy to reduce the size of the tumor. In some cases, those with non-B cell tumors may have hormone therapy with growth hormone, glucocorticoid, or octreotide to also lessen hypoglycemic episodes. Post-gastric bypass hypoglycemia can be prevented by eating smaller, more frequent meals, avoiding sugar-filled foods, as well as medical treatment with an alpha-glucosidase inhibitor, diazoxide, or octreotide. Some causes of hypoglycemia require treatment of the underlying cause to best prevent hypoglycemia. This is the case for insulinomas which often require surgical removal of the tumor for hypoglycemia to remit. In patients who cannot undergo surgery for removal of the insulinoma, diazoxide or octreotide may be used.
== Awards == The Norm Smith Medal was awarded to Brian Lake of Hawthorn. The Brownlow Medal was awarded to Gary Ablett Jr. of Gold Coast, who received 28 votes. The AFL Rising Star was awarded to Jaeger O'Meara of Gold Coast, who received 44 votes. The Coleman Medal was awarded to Jarryd Roughead of Hawthorn, who kicked 68 goals during the home and away season. The McClelland Trophy was awarded to Hawthorn for the second year in a row. The Wooden Spoon was "awarded" to Greater Western Sydney for the second year in a row. The AFL Players Association awards The Leigh Matthews Trophy was awarded to Gary Ablett Jr. of Gold Coast for a record fifth time. The Robert Rose Award was awarded to Joel Selwood of Geelong for the second year in a row and third time overall. The Best Captain was awarded to Joel Selwood of Geelong. The Best First-Year Player was awarded to Jaeger O'Meara of Gold Coast. The AFL Coaches Association Awards were as follows: The Player of the Year Award was given to Scott Pendlebury of Collingwood, who received 96 votes. The Allan Jeans Senior Coach of the Year Award was awarded to Ken Hinkley of Port Adelaide The Assistant Coach of the Year Award was awarded to Robert Harvey of Collingwood. The Development Coach of the Year Award was awarded to Chris Maple of Western Bulldogs. The Support Staff Leadership Award was awarded to Stephen Wells of Geelong. The Lifetime Achievement Award was awarded to George Stone. The Best Young Player Award was awarded to Jeremy Cameron of Greater Western Sydney.
=== Microbead-based immobilization === Microbead-based immobilization is a modular technique in that it allows the investigator to decide whether they wish to fish for protein targets from the proteome or drug-like compounds from chemical libraries. The macroscopic properties of microbeads make them amenable to relatively low labor enrichment applications, since they are easily to visualize and their bulk mass is readily removable protein solutions. Microbeads were historically made of inert polymers, such as agarose and dextran, that are functionalized to attach a bait of choice. In the case of using proteins as bait, amine functional groups are common linkers to facilitate attachment. More modern approaches have benefitted from the popularization of dynabeads, a type of magnetic microbead, which enable magnetic separation of bead-immobilized analytes from treated samples. Magnetic beads exhibit superparamagnetic properties, which make them very easy to remove from solution using an external magnet. In a simplified workflow, magnetic beads are used to immobilize a protein target, then the beads are mixed with a chemical library to screen for potential ligands. High-affinity ligands bind to the immobilized target and resist removal by washing, so they are enriched in the sample. Conversely, a ligand of interest can be immobilized and screened against proteome proteins by incubation with a lysate.
Sources: en.wikipedia.org
27 August – A large fire destroys Clune Park Primary School in Port Glasgow. 28 August – The Scottish COVID-19 Inquiry, chaired by Lord Brailsford, formally gets under way with preliminary hearings at Edinburgh's Murrayfield Stadium. BBC Scotland reports that the number of adults in Scotland receiving prescriptions for Attention deficit hyperactivity disorder (ADHD) has increased sevenfold over the last decade. 29 August – Data released by National Records of Scotland indicate there were 1,276 alcohol-related deaths in Scotland during 2022, a rise on the previous year, with figures at a 14-year high. 31 August – The first case of a new COVID-19 variant, BA.2.86, is detected in Scotland.
Some have active camouflage that changes with need. Distraction eye, many fish have spot on the tail to fool potential predators and prey; both are not sure which is the front, the direction of travel. Gills appear in unrelated fish, some amphibians, some crustacean, aquatic insects and some mollusk, like freshwater snails, squid, octopus.
== Plot == Jason sits on a bench in New York City waiting for someone to arrive. Jason's voiceover explains that he has been waiting for a long time, but to explain why, he needs to go back to the beginning. Jason tells the audience that every relationship reaches the "So..." moment, where someone in the relationship will want to take the relationship to a more serious place. At that point, Jason knows the relationship is over, as he is not ready for a serious relationship. Jason works with his best friend Daniel at a publishing house designing book covers. Their doctor friend Mikey, who has been married since the end of college, comes to them after his wife Vera requests a divorce. They decide to go out to a bar and celebrate Mikey now being single. The group meets up with Daniel's female wingman, Chelsea, as they try to get Mikey's mind off of his wife. Mikey meets a girl with glasses, while Jason meets Ellie, and hits it off with her after teasing another man that was trying to buy her a drink. Mikey gets "Glasses" number, but puts off calling her, resolving to work it out with Vera. Jason sleeps with Ellie, but leaves her apartment in a hurry after jumping to the mistaken conclusion that she is a prostitute. The next day, Jason and Daniel make a book cover pitch to a new author, who happens to be Ellie. Ellie is hurt and enraged that he did not stay the whole night. Jason tries to make it up to her, but she refuses. Jason, Daniel and Mikey then make a pact to stay single together for the foreseeable future.
Sources: en.wikipedia.org
No. It is a synthetic analogue modeled on the first 29 residues of human GHRH. The substitutions and any linker are laboratory modifications rather than features of the endogenous peptide.
Early development used the albumin-binding form, and a shorter variant was later discussed under the same label. Because the two differ in half-life and handling, ambiguity arises whenever a source omits the variant designation.
The compound derives from that fragment but is not identical to it. The parent fragment lacks the stabilizing substitutions, so its degradation rate and duration of action differ noticeably.
The names are often used interchangeably in casual writing, but they are not strictly identical. Modified GRF(1-29) refers to the unconjugated analogue carrying only the four substitutions. The version sold as CJC-1295 with DAC includes the albumin binding linker and clears much more slowly.